Column-switching high-performance liquid chromatographic method for the determination of SK&F 106203 in human plasma after fluorescence derivatization with 9-anthryldiazomethane.
A sensitive and selective high-performance liquid chromatographic method was developed for the determination of SK&F 106203 3-(2-carboxyethylthio)-3-[2-(8-phenyloctyl)phenyl]propanoic acid, a potent peptidoleukotriene end organ receptor antagonist, in human plasma. The method involves isolation of SK&F 106203 and the internal standard (SK&F 104736) from plasma samples by liquid-liquid extraction prior to derivatization with 9-anthryldiazomethane. The derivatized samples were first subjected to a solid-phase extraction procedure prior to injection onto a short silica column, which is part of a chromatographic system equipped with an automated column-switching device. Column switching was used to heart-cut the chromatographic zone containing the peaks of interest from this first column and transfer it to an analytical silica column for further chromatographic separation. The peaks were quantified with an in-line fluorometer by measuring the fluorescence emission intensity at 415 nm after excitation at 365 nm. An on-column detection limit of 0.625 ng was achieved for SK&F 106203 by optimizing the derivatization and chromatography conditions. The limit of quantification for SK&F 106203, using 250 microliters of plasma, was 20 ng/ml. Linear response in SK&F 106203/internal standard peak-height ratios was observed for SK&F 106203 concentrations ranging from 10 to 5000 ng/ml of plasma. Precision and accuracy were within 5% across the calibration range. The assay was sufficiently sensitive, accurate, and precise to support pharmacokinetic studies in humans.